Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Aria, Sequenom; Nanosphere; BGI; Epitomics; Waters

NEW YORK (GenomeWeb News) – Aria Diagnostics has filed a suit against Sequenom claiming that the firm is overly aggressive in its enforcement of a broad patent related to the use of circulating cell-free DNA in maternal plasma to diagnose fetal aneuploidies. San Jose, Calif.-based Aria has requested a declaratory judgment that a test it is developing to diagnose fetal aneuploidies does not infringe Sequenom's patent. For more on this story, see GenomeWeb Daily News sister publication Clinical Sequencing News.

In a subsequent filing with the US Securities and Exchange Commission, Sequenom said that it intends to "vigorously defend against the judicial declaration sought in the complaint."

Nanosphere this week said that it has obtained the CE Mark for its Gram-Positive Blood Culture Nucleic Acid Test. The Northbrook, Ill.-based firm said the test provides genus and species level detection for a broad panel of the most clinically significant gram-positive bacteria and also detects several markers for antibiotic resistance, including the mecA, vanA, and vanB genes. The BC-GP test runs on Nanosphere's Verigene molecular diagnostics system.

BGI said this week that it, along with Inner Mongolia Agricultural University and Inner Mongolia University for the Nationalities, have completed the first sequence of the Mongolian genome. The researchers used a DNA sample from an adult male who belongs to the Mongolian "Royal Family" and is a 34th generation descendant of Genghis Khan. BGI did not disclose when the sequence would be published.

Epitomics announced this week that it has completed a collaboration with the University of California, Davis, which has led to the development of a new label-free optical microarray detection platform for high-throughput measurements of antibody-antigen interactions.

Waters said this week that it has donated one of its Acquity TQD Systems to the University of Buffalo's School of Pharmacy and Pharmaceutical Sciences for its research into the treatment of HIV and AIDS-related illnesses in sub-Saharan Africa.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.